国产比伐卢定在老年急性冠脉综合征患者介入术中治疗效果
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2018年第2期
- 页码:
- 159-161,169
- 栏目:
- 临床研究
- 出版日期:
- 2018-02-15
文章信息/Info
- Title:
- The therapeutic effect of bivalirudin during primary percutaneous coronary intervention in elderly patients with acute coronary syndrome
- Author(s):
- TONG Jian-wen; CAI Guo-cai
- （Department of Cardiology, First Affiliated Hospital, Chengdu Medical College, Chengdu 610500, Sichuan, China）
- 关键词:
- 比伐卢定; 肝素; 老年; 急性冠脉综合征; 经皮冠状动脉介入治疗
- 分类号:
- R541.4
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的 研究老年（年龄>65岁）急性冠脉综合征（ACS）患者在经皮冠脉介入（PCI）治疗术中使用国产比伐卢定的安全和有效性。方法 本研究通过回顾性分析我院35例PCI术中应用比伐卢定的老年ACS患者的临床资料，按1∶1匹配选取同期35例PCI治疗过程中常规应用普通肝素的老年ACS患者作为对照组，分析术后30 d内的主要不良心脑血管事件(major adverse cardiac and cerebrovascular events，MACCE)及出血并发症的发生情况。结果 两组临床资料对比，差异无统计学意义。术后30 d内MACCE发生率分别为4例（11%）和5例（14%），差异无统计学意义；出血并发症发生率分别为1例（3%）和6例（17%），比伐卢定组优于普通肝素组（P<0.05）。结论 老年ACS患者PCI术中使用比伐卢定与普通肝素相比，可减少术后30d内的出血事件发生率，且不增加MACCE的风险。
- Abstract:
- AIM AIMTo evaluate the efficiency and safety of bivalirudin during percutaneous coronary intervention (PCI) in elderly patients (Age>65) with acute coronary syndrome (ACS). METHODS Medical records were analyzed in 35 patients given bivalirudin during PCI. The same type of records were screened in which unfractionated heparin (UFH) was used during PCI at a ratio of 1∶1 for a control group of 35 patients.The main endpoint events included major adverse cardiac and cerebrovascular events (MACCE) and severe bleeding complications at 30 days. RESULTS There were no significant differences between the two groups.The incidences of MACCE (11% vs. 14%), which was 4 for bivalirudin and 5 for heparin at 30 days, demonstrated no statistical significance.The incidences of bleeding (3% vs. 17%, P<0.05), which was 1 for bivalirudin and 6 for heparin, showed that the bivalirudin group is superior to the heparin group. CONCLUSION The use of bivalirudin resulted in a decrease in bleeding events without significant difference in MACCE compared with heparin alone at 30 days.
参考文献/References
[1]Genereux P,Giustino G,Witzenbichler B,et al.Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention[J].J Am Coll Cardiol,2015,66(9):1036-1045.
[2]Eikelboom JW,Mehta SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes[J].Circulation,2006,114(8):774-782.
[3]Ortel TL.Heparin-induced thrombocytopenia:when a low platelet count is a mandate for anticoagulation[J].Hematology Am Soc Hematol Educ Program,2009,2009(1):225-232.
[4]Steinmetzer T,Sturzebecher J.From fibrinogen and hirudin to synthetic anticoagulants.Rational design of thrombin inhibhors[J].Pharm Unserer Zeit,2004,33(3):196-205.
[5]Sciulli TM,Mauro VF.Pharmacology and clinical use of bivalirudin[J].Ann pharmacother,2002,36(6):1028-1041.
[6]Lemesle G,De Labriolle A,Bonello L,et al.Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention[J].Catheter Cardiovasc Interv,2009,74(3):428-435.
[7]Lopes RD,Alexander KP,Manoukian SV,et al.Advanced age,antithrombotic strategy,and bleeding in non-st-segment elevation acute coronary syndromes:Results from the acuity(acute catheterization and urgent intervention triage strategy)trial[J].J Am Coll Cardiol,2009,53(12):1021-1030.
[8]Lincoff AM,Kleiman NS,Kereiakes DJ,et al.Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs.heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: Replace-2 randomized trial[J].JAMA,2004,292(6):696-703.
[9]关绍义,王晓燕,李 晶,等.老年急性心肌梗死患者急诊经皮冠状动脉介入治疗围术期应用比伐芦定的疗效与安全性:BRIGHT研究预设亚组分析[J].中国介入心脏病学杂志,2016,24(8):421-426.
备注/Memo
- 备注/Memo:
- 收稿日期：2017-05-18.通讯作者：蔡国才，副主任医师，主要从事心血管病介入治疗研究 Email：56402562@qq.com 作者简介：童健文，住院医师，硕士生 Email：313140364@qq.com
常用功能
统计/Statistics
- 摘要浏览/Viewed650
- 评论/Comments
